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when comparing AP2 + MS therapy with MS monotherapy.
CONCLUSIONS: In terms of non-index medication health-
related costs, AP2 monotherapy was more cost saving than MS
monotherapy in the treatment of bipolar disease. In terms of
non-index medication bipolar-related costs, AP2 monotherapy
and AP2 + MS therapy was more cost saving than MS monother-
apy. However, when the cost of AP2 treatment was included, no
signiﬁcant differences were found.
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OBJECTIVES: To evaluate the direct health care costs associated
with olanzapine, risperidone, and quetiapine monotherapy
among patients diagnosed with bipolar disorder (ICD-9: 296.4x-
296.8x). METHODS: Using a sample drawn from the NC Med-
icaid Claims database during August 2000 through January
2005. This study included patients with a bipolar-related diag-
nosis who were naïve to atypical antipsychotic treatment and
were without a bipolar-related medical visit or hospitalization
during 90 days prior to treatment initiation. Patients were fol-
lowed for 12 months after initiation of atypical antipsychotic
monotherapy (index drug). Costs of index drug, all bipolar-
related medical care, and all health-related costs, both including
and excluding index drug, were examined in the 12 month treat-
ment period using Generalized Linear Model with Gamma 
Distribution and Log link. To account for potential confounds,
the model included several covariates. RESULTS: A total of 838
continuously eligible patients met the inclusion criteria (393
olanzapine, 262 risperidone and 183 quetiapine). The costs of
index drug for patients taking olanzapine were 43% (P < 0.0001)
and 19% higher (p < 0.0001) than risperidone and quetiapine,
respectively. In terms of total health-related cost there was no
difference between patients treated with olanzapine and those
treated with risperidone or quetiapine, including or excluding
index drug. In terms of all bipolar-related medical care costs, the
inclusion of index drug led to 15.2% (p < 0.04) higher costs 
for patients receiving olanzapine compared to risperidone, 
primarily due to the higher acquisition cost of olanzapine. 
CONCLUSIONS: Despite signiﬁcantly higher acquisition costs
of olanzapine when used as mono-therapy for the treatment of
bipolar disorder, total health-related costs with and without
index drug were similar for olanzapine, risperidone and queti-
apine. Bipolar-related medical costs excluding index drug were
also similar for olanzapine, risperidone, and quetiapine treat-
ment. However, the inclusion index drug costs resulted in higher
bipolar-related medical costs for patients receiving olanzapine
compared to risperidone.
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OBJECTIVE: To examine the acute adverse outcomes and direct
health care costs among patients with Alzheimer’s disease (AD)
using a retrospective, administrative claim database.
METHODS: We identiﬁed an over-age-65 population with phar-
macy and medical beneﬁts enrolled in a large, US, geographically
diverse, commercial managed care plan between May 2001 and
December 2002. AD patients had at least one claim with an AD
diagnosis or one ﬁlled prescription for medication used exclu-
sively for AD treatment. This claim identiﬁed the index date. A
control cohort consisted of non-AD patients with no dementia
diagnosis over the pre- and post-index periods randomly
matched (3 :1) to the AD patients by age, gender, plan location,
and length of enrollment. The ﬁrst claim in the period identiﬁed
the index date. All patients included in the study had a 12-month
pre-index period, and a minimum of 30-days follow-up. We
compared the prevalence of acute adverse outcomes and comor-
bidities between the AD and control cohorts. Additionally, we
used a two-part model (one equation estimating the probability
of any costs, and a generalized linear model with a gamma dis-
tribution and log-link function estimating the level of costs) to
examine differences in adjusted annualized total health care costs
between the AD patients and the controls. RESULTS: Both the
AD patients (N = 4,550) and the controls (N = 13,650) had a
mean age of 79 years. Approximately 70% of AD patients were
identiﬁed based on an AD prescription. AD patients had a higher
risk of fracture, accidental fall, and urinary tract infection than
the controls. Annual adjusted total health care costs per patient
were approximately $1418 greater for the AD cohort. 
CONCLUSIONS: AD patients had signiﬁcantly greater risk 
of acute adverse outcomes and more health care resource 
utilization than age- and gender-matched controls in a large
managed care plan.
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OBJECTIVES: To examine the direct medical costs of newly
diagnosed patients with Alzheimer’s disease (AD) using retro-
spective health care claims data. METHODS: This study exam-
ined individuals aged 65 years and over with pharmacy beneﬁts
who had at least one claim with an AD diagnosis and were
enrolled in commercially-insured and nationally-dispersed
Medicare Risk plans between January 1999 and November
2003. Each AD patient had an “index date” where the ﬁrst AD
claim was observed, a 12-month pre-index period, and a
minimum 30-day follow-up. A control group consisted of indi-
viduals who had no AD or dementia over the study period and
were randomly matched (2 :1) to AD patients based on age,
gender, and follow-up duration. The Charlson Comorbidity
Index was used to examine the burden of comorbid medical con-
ditions in the pre-index period. The primary measures of inter-
est were annualized health care resource utilization and costs; a
generalized linear model with a gamma distribution and log-link
function was used to compare costs between the AD and control
groups over the follow-up period. RESULTS: Both AD patients
(n = 2475) and controls (n = 4950) were aged 82 years on
average; 38% were male. AD patients had signiﬁcantly more
comorbid medical conditions than controls (mean Charlson
score 1.6 vs. 1.2); the prevalence of diabetes, heart and vascular
problems also was higher in the AD group. Inpatient costs con-
tributed primarily to total annualized costs among AD patients,
while outpatient costs dominated among controls. Average
adjusted annualized costs for AD patients were more than ﬁve-
fold higher compared to controls, driven primarily by inpatient
costs ($21,150 vs. $4,053 for AD vs. control, respectively).
CONCLUSIONS: AD patients have a signiﬁcantly greater
